Utopia SIS

A Società di Investimento Semplice is an Italian investment-company structure designed for closed-end, early-stage vehicles. It operates like a permanent-capital balance-sheet investor rather than a traditional blind-pool fund — Utopia SIS invests off its own equity base, does not face standard GP/LP fund-life constraints, and does not run continuous external fundraising cycles. This architecture aligns with long-duration biotech outcomes, where portfolio tempo is set by clinical milestones rather than fund redemption schedules.

Investment governance sits with the board of directors, which as of the firm's public disclosures includes President Stefano Cattorini, CEO and Executive Vice President Antonio Falcone, and board members Sergio Abrignani, Giacomo Spissu, Rodolfo Quagliuolo, Antonio Danieli, and Giampaolo Girotti. Scientific evaluation is reinforced by Scientific Venture Partner Sergio Abrignani and a scientific advisory board composed of Prof. Andrea Ballabio, Prof. Antonio Lanzavecchia, and Prof. Pier Giuseppe Pelicci. The firm has not published a formal investment committee structure beyond the board.

No. Utopia SIS restricts its mandate to life sciences: disease-modifying drugs, medical devices, diagnostic tools and biomarkers, and cross-border AI applications in biotechnology. Its publicly named portfolio companies — including Novavido, PerFormS, Lighthouse Biotech, Drug Discovery and Clinic, CaSRevolution, and T-One Therapeutics — all sit within the life-sciences vertical. There is no disclosed exposure to fintech, enterprise software, climate, or other generalist venture categories.

The firm states it builds origination pipelines through a transversal network of national and international accelerators, incubators, primary university institutes, research centers of excellence, and other venture capital funds. Italian Angels for Biotech is cited as a frequent co-investment partner, suggesting a syndication-based, network-driven approach rather than proprietary cold-outreach origination. The portfolio page emphasizes selection of projects where scientific evaluation is the focal point and where the therapies target health needs currently without valid alternatives.

Fondazione Golinelli and Fondazione di Sardegna appear as governance and co-investment ecosystem partners rather than purely financial limited partners. Andrea Zanotti, President of Fondazione Golinelli, and Antonello Cabras, President of Fondazione di Sardegna, are linked to Utopia's governance perimeter in prior altss research records. The firm also maintains a physical presence at Opificio Golinelli, a multi-purpose innovation and education hub in Bologna, reinforcing an institutional integration with the foundation's broader mission in science and entrepreneurship.

No. Utopia SIS does not publish AUM, aggregate capital deployed, or fund-size targets on its website or in publicly available records. The firm's investment-company structure means capital is deployed from its own balance sheet, and the lack of disclosed fundraising closes one typical avenue for inferring asset scale. The AUM estimate is therefore marked as undisclosed.

The firm targets Seed and Series A stages, focusing on early-stage life-science companies. Investment structures include direct equity stakes in startups, consistent with the SIS format and the profile of the six named portfolio companies on its website.